Fuda Cancer Hospital
Mastectomy in China typically costs from $8,500 to $16,500 depending on the surgical technique. Prices are influenced by the hospital tier, city location, and whether reconstruction is performed simultaneously. In the US, similar procedures cost around $35,000 on average. Patients can find substantial savings in China, with a price discount of approximately 64%.
Bookimed Expert Insight: Choosing specialized oncology centers provides significant value for complex cases. Fuda Cancer Hospital in Guangzhou is JCI-accredited and treats over 30,000 international patients. They specialize in advanced and late-stage cancers using minimally invasive cryosurgery and NanoKnife. Their standard mastectomy procedures start around $4,150. This price often includes surgical fees, lab tests, and hospital stays. Focusing on such centers ensures global safety standards at local Chinese market rates.
| China | Turkey | Austria | |
| Mastectomy | from $8,500 | from $1,310 | from $10,000 |
Day 1 - Arrival
Day 2 - Pre-operation
Day 3 - Mastectomy
Day 4 - Post-operation
Week 1 - 2 - Rehabilitation
Week 3 - 6 - Rehabilitation
Week 7 - 12 - Rehabilitation
Each case is individual, please consult with your physician for specific details.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Dr. Niu Lizhi is the President and chief surgeon at Fuda Cancer Hospital in Guangzhou. He has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures. Dr. Niu specializes in minimally invasive oncology for lung, pancreatic, and liver cancers. He treats patients ranging from early childhood through age 94.
Written by Kateryna Zamkovska
It is a surgical procedure to remove one or both breasts, partially or completely, to treat or prevent breast cancer.